Announced details
Treatment of relapsed or refractory acute myeloid leukemia (R/R AML)
The company will present clinical study abstracts at the ASH 2026 Annual Meeting. Other capital and personnel relationships are Not disclosed.
An international academic conference in the field of hematology. The ASH 2026 Annual Meeting will be held in New Orleans, Louisiana, United States, from 12 to 15 December 2026.
New Orleans, Louisiana, United States (venue for the ASH 2026 Annual Meeting)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
ASH 2026 Annual Meeting online program (abstract IDs: 682760, 682770)
| Item | Details |
|---|---|
| Names of Products / Services Covered | DFP-10917, Venetoclax |
| Counterparty | American Society of Hematology (ASH) |
| Counterparty overview | An international academic conference in the field of hematology. The ASH 2026 Annual Meeting will be held in New Orleans, Louisiana, United States, from 12 to 15 December 2026. |
| Relationship with the Company | The company will present clinical study abstracts at the ASH 2026 Annual Meeting. Other capital and personnel relationships are Not disclosed. |
| Launch date | 12 and 14 December 2026 (scheduled presentation dates) |
| Applicable area | Treatment of relapsed or refractory acute myeloid leukemia (R/R AML) |
| Location | New Orleans, Louisiana, United States (venue for the ASH 2026 Annual Meeting) |
| Source | ASH 2026 Annual Meeting online program (abstract IDs: 682760, 682770) |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This will be an important opportunity to communicate the clinical development data obtained to date on DFP-10917 monotherapy and combination therapy with venetoclax to the international hematology research community.